Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Absent, added, afforded, agonist, Amnesteemtm, annum, answered, appellate, await, awaiting, belief, bond, Bulletin, buyback, Canada, carbidopa, central, Cephalon, chloride, closure, collaborate, collaboration, collaborative, confidential, consummated, contributor, copyand, DEA, disclosed, Ditropan, drawn, Dutch, eligible, EMSAM®Approval, excessive, fall, fee, fixed, flexibility, flow, foreseeable, Forest, Hawaii, indemnity, indenture, inflated, involuntary, IRC, IRS, jointly, junior, jury, landscape, Lastly, led, levodopa, LIBOR, lien, loan, mandatory, merge, Minnesota, Mississippi, Missouri, narcotic, observed, opportunity, outlicensing, oxybutynin, pain, parent, passed, penalty, persuasive, pledge, power, prepayment, prime, priority, procurement, quota, rank, ratio, recast, Reclassification, rectified, redirect, refinance, refusal, repayment, resolution, restructuring, reverted, SAB, satisfactory, sector, semiannually, senior, sooner, standard, stop, storage, succeed, suggested, survived, Task, tender, tendered, tendering, turn, twelve, unamortized, unconditional, unpaid, unused, upfront, upheld, Usage, USW, verdict, vulnerable, willfully, withstand, XL
Removed:
bioequivalency, Biovail, borrow, Buspar, buspirone, cardiology, carried, Compensationand, core, daily, dermatology, Digitek, discretion, efficient, Eldepryl, emphasize, equally, equitable, finalized, insure, Interbank, invest, irrevocable, lender, London, neurology, Northern, notice, overlap, Parkinson, partnership, Penederm, petition, Pfizer, phenytoin, prescriber, presence, principle, professional, putative, reaching, renewed, servicing, settled, stable, Taxol, therapeutically, unclear, unrelated, utilized, voluntarily
Filing tables
Filing exhibits
- 10-K Annual report
- 10.4 EX-10.4.D
- 10.4 EX-10.4.E
- 10.5 EX-10.5
- 10.6 EX-10.6.B
- 10.7 EX-10.7.B
- 10.8 EX-10.8.B
- 10.9 EX-10.9.B
- 10.10 EX-10.10.B
- 10.11 EX-10.11.B
- 10.12 EX.10.12.B
- 10.13 EX-10.13.B
- 10.14 EX-10.14.B
- 10.15 EX-10.15.B
- 10.19 EX-10.19.C
- 10.20 EX-10.20.C
- 10.21 EX-10.21.C
- 10.22 EX-10.22.C
- 10.23 EX-10.23
- 10.24 EX-10.24.B
- 21 EX-21
- 23 EX-23
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32 EX-32
Related press release
Mylan similar filings
Filing view
External links
EXHIBIT 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Nos.333-35887,333-42182,333-43081,333-65327,333-65329,333-98811,333-111076 and333-111077 on Form S-8 of our reports dated May 12, 2006, relating to the consolidated financial statements and financial statement schedule of Mylan Laboratories Inc. and management’s report on the effectiveness of internal control over financial reporting, appearing in this Annual Report on Form 10-K of Mylan Laboratories Inc. for the year ended March 31, 2006.
/s/ Deloitte & Touche LLP
Pittsburgh, Pennsylvania
May 12, 2006
75